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Expression of voltage-gated sodium channel in primary tumors and corresponding 
metastases in the Copenhagen rat model of prostate cancer
Prostat kanseri Copenhagen sıçan modelinin primer tümörleri ve metastazlarında voltaj kapılı 
sodyum kanal ekspresyonu
Şenay Yıldırım
ÖZET
Amaç: Artan miktardaki kanıt prostat kanser (PCa) hüc-
relerinin voltaj kapılı sodyum kanalları (VGSCs)’na sahip 
olduğunu  ve  bu  kanalların  hastalığın  metastatik  ilerle-
mesine  katkıda  bulunduğunu  göstermektedir.  Mevcut 
çalışmada,  VGSC’lerin  karsigonezde  ve  metastazdaki 
heterotopik  ekspresyonunu  araştırmak  amaçlanmıştır. 
Güçlü metastatik sıçan Mat-LyLu PCa hücrelerinde in vit-
ro olarak gözlemlenen VGSC ekspresyonunun, bu hücre-
lerin sıçanlara subkuten enjekte edildiğinde primer tümör 
oluştuğunda ve hücreler akciğerlere metastaz yaptığında 
korunup korunmadığı, değerlendirilmiştir. 
Yöntemler: PCa modeli Copenhagen ırkı erkek sıçan-
larda  güçlü  metastatik  Mat-LyLu  hücrelerinin  subkuten 
implantasyonu ile oluşturulmuştur. VGSC eksprsyonu bu 
modelde moleküler biyolojik ve immünokimyasal yöntem-
lerle araştırılmıştır. 
Bulgular: Ters transkripsiyon PCR ve immünohistokimya 
yöntemleri VGSC ekspresyonunun Mat-LyLu primer pros-
tat tümörlerinde korunduğunu ve akciğer metatsazlarında 
da bu ekspresyonun devam ettiğini, mRNA ve protein dü-
zeyinde göstermiştir. 
Sonuç: Sonuçlar, VGSC’lerin PCa’nin metastatik ilerle-
mesindeki baskın rolü ile uyumludur ve ‘kanserin ilerle-
mesinde VGSC’lerin rolü’ hipotezini tutarlı bir şekilde des-
teklemektedir. 
Anahtar kelimeler: Prostat kanseri, voltaj-kapılı sodyum 
kanalı, primer tümör, metastaz
ABSTRACT
Objective:  Increasing  evidence  indicates  that  prostate 
cancer (PCa) cells possess voltage-gated sodium chan-
nels (VGSCs) and these channels contribute to the meta-
static progression of the disease. In the present study, it 
was aimed to investigate the heterotopic expression of 
VGSCs in carcinogenesis and metastasis. It was evaluat-
ed whether the expression of VGSC in strongly metastatic 
rat Mat-LyLu PCa cells observed in vitro is also conserved 
when these cells form primary tumors and metastasize to 
the lungs upon their subcutaneous injection in rats.
Methods: PCa model was induced in male Copenhagen 
rats by subcutaneous implantation of strongly metastatic 
Mat-LyLu cells. The expression of VGSCs was studied 
in the model utilizing molecular biological and immuno-
chemical techniques.
Results: Reverse transcription PCR and immunohisto-
chemistry showed that the expression of VGSC is con-
served in the primary prostate tumors of Mat-LyLu and 
not eliminated in the corresponding lung metastases at 
both the mRNA and protein level. 
Conclusion: The results are consistent with the predomi-
nant role of VGSC in the metastatic progression of PCa 
and consistently support the VGSC hypothesis of cancer 
progression. J Clin Exp Invest 2013; 4 (4): 422-428
Key words: Prostate cancer, voltage-gated sodium chan-
nel, primary tumor, metastasis
INTRODUCTION
Prostate cancer (PCa) is one of the most frequent 
malignancies  in  men.  The  major  problem  arising 
from PCa is its propensity to metastasize. Androgen 
deprivation therapy, which causes initial regression, 
is the cornerstone of metastatic PCa treatment due 
to  the  androgen  dependent  nature  of  PCa  cells. 
Very  frequently  however,  androgen-independent 
cancers emerge and almost all tumors progress to 
the lethal stage of the disease [1]. Therefore, an un-
derstanding of the metastatic mechanisms in PCa 
is important to the development of novel therapies.
Currently, there is a considerable body of evi-
dence emphasizing the importance of voltage-gat-
ed sodium channels (VGSCs) in the progression of Yıldırım. Expression of voltage-gated sodium channel in primary tumors 423
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PCa. This evidence has previously described the 
presence of VGSCs in strongly metastatic rat Mat-
LyLu [2] and human PC-3 [3] PCa cell lines using 
electrophysiological and molecular methods [4,5]. It 
has been shown that these cells specifically over-
express the Nav1.7 subtype of VGSCs [4]. VGSC 
expression has also been reported in clinical PCa 
specimens [6] and Nav1.7 mRNA and protein levels 
are significantly upregulated in the prostatic tissues 
of PCa patients compared to non-PCa prostate tis-
sues [7]. VGSCs are also expressed in several oth-
er types of carcinoma including breast cancer [8,9], 
small cell lung cancer [10], non-small lung cancer 
[11],  melanoma  [12],  glioma  [13],  mesothelioma 
[14],  ovarian  cancer  [15],  colon  cancer  [16]  and 
cervical cancer [17]. Importantly, the expression of 
VGSC has been shown to contribute to the metas-
tasis of these carcinomas by enhancing a number 
of metastatic cell functions in vitro such as invasion 
[9,16,18,19], directional motility [20,21], metastatic 
cell morphology [22], endocytosis [9,10,23] and de-
tachment [24]. It is clear from these studies that a 
variety of VGSC isoforms are functional in different 
cancer cell types. For example, while Nav1.7 seems 
to be essential for PCa metastatic behaviors [5,25], 
the Nav1.5 subtype is critical for breast, ovarian and 
colon cancer invasiveness [15,16,26]. In the stud-
ies of clinical samples, it was shown that Nav1.5 
expressions in primary breast and ovarian cancer 
specimens strongly correlate with the presence of 
lymph node metastasis [9,15]. 
Metastasis,  a  complex-multistep  process,  re-
quires complex experimental systems for its study 
and  the  modeling  of  this  biological  complexity  is 
possible using animal models [27]. Recently, in the 
first in vivo experimental study, it was reported that 
the injection of low doses of tetrodotoxin (TTX), a 
specific VGSC blocker, into primary tumors signifi-
cantly suppressed metastasis to lung and prolonged 
lifetime in the Mat-LyLu Copenhagen rat model of 
PCa [28]. However, it is unclear whether the VGSC 
expression is present in the metastatic lesions or 
whether clones, which do not express VGSC are 
responsible for the generation of metastases. The 
objective of this study was to evaluate the VGSC 
hypothesis of cancer progression by extending the 
in vivo approach to molecular studies. It was exam-
ined the expression status of VGSC in the strongly 
metastatic rat Mat-LyLu PCa cells, primary prostate 
tumors of Mat-LyLu and corresponding lung metas-
tases. The results provided a substantial contribu-
tion to the in vivo evaluation of the hypothesis.
METHODS
Cell Culture
The strongly metastatic Mat-LyLu rat prostate can-
cer cell line was cultured at 37°C with 5% CO2 in 
RPMI-1640  medium  supplemented  with  1%  fetal 
bovine  serum  (FBS;  Invitrogen/Gibco),  250  nM 
dexamethasone (Sigma-Aldrich) and 2 mM L-gluta-
mine (Invitrogen/Gibco) [25]. 
Tumor implantation and dissection
All animal procedures were carried out under the 
ethical  rules  of  Istanbul  University.  Experiments 
were  carried  out  on  2.5-month-old  male  Copen-
hagen  rats  weighing  200-220g  (Charles  River, 
Suizfeld,  Germany).  Mat-LyLu  cells  were  freshly 
harvested and resuspended in fresh supplemented 
medium.  To  generate  a  PCa  tumor  model  2x105 
tumor cells were implanted into the right flank of 
Copenhagen rats. Twenty days after tumor cell in-
oculation, the rats were euthanized with isoflurane. 
Primary tumors and lung metastases were quickly 
removed from the euthanized animals and speci-
mens (free of necrotic material) were frozen in liquid 
nitrogen and stored at −80°C for PCR and immu-
nohistochemical studies. Portions of primary tumors 
and lung metastases were also fixed in 10% neutral 
buffered  formaldehyde  and  embedded  in  paraffin 
blocks for histological evaluation and other immu-
nohistochemical studies. 
Reverse transcription polymerase chain 
reaction (RT-PCR)
Total RNA was extracted from the Mat-LyLu cells 
and frozen primary tumor and lung metastases tis-
sues using TRIzol Reagent (Invitrogen) according 
to the manufacturer’s specifications. The quantity 
and  quality  of  the  extracted  RNA  in  the  samples 
were determined with an ND-1000 Spectrophotom-
eter (Labtech). One microgram of total RNA was 
used  as  the  substrate  for  single-stranded  cDNA 
synthesis using Superscript II reverse-transcriptase 
(Invitrogen) with random hexamer mix (Invitrogen). 
The PCR reactions were prepared using 5 µl cDNA, 
each primer and TaqDNA polymerase (Qiagen) at 
a final volume of 20 µl. The reaction mixture was 
then subjected to PCR amplification for 35 cycles 
consisting of heat denaturation, annealing and ex-
tension [4,7]. Cytochrome b5 reductase (Cytb5R), 
which has been shown to remain unchanged in rat 
PCa7, was used to control for variables including 
sample-to-sample  differences  in  the  quality  and Yıldırım. Expression of voltage-gated sodium channel in primary tumors 424
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quantity  of  the  RNA  and  reverse-transcription  ef-
ficiency.  In  each  PCR  reaction,  controls  without 
reverse  transcriptase  and  without  added  cDNA 
were  also  performed.  The  Nav1.7  (the  major 
VGSCα subtype in Mat-LyLu cells) primers were: 
5’-TTCATGACCTTGAGCAACCC-3’ (Forward) and 
5’-TCTCTTCGAGTTCCTTCCTG-3’ (Reverse); an-
nealing  temperature,  60°C;  and  Cytb5R  primers 
were:  5’-ACACGCATCCCAAGTTTCCA-3’  (For-
ward) and 5’-CATCTCCTCATTCACGAAGC-3’ (Re-
verse); annealing temperature, 60°C.4,7 PCR prod-
ucts were then analyzed by electrophoresis in 1.5% 
agarose gel and visualized by UV trans-illumination 
(Uvitec).
Immunocytochemistry
The presence of VGSC protein in Mat-LyLu cells 
was examined by immunocytochemistry using an 
“anti-sodium  channel”  polyclonal  antibody.  This 
antibody  (Upstate-Millipore,  Cat  no:  06-811)  rose 
in  rabbits  against  the  highly  conserved  cytosolic 
linker region between domains III and IV (peptide 
sequence TEEQKKYYNAMKKLGSKKP, amino ac-
ids 1490–1508) of known VGSCs α-subunits. The 
cells were cultured for 48 hours on coverslips. The 
samples  were  fixed  with  4%  paraformaldehyde 
in PBS and then blocked with 10% normal swine 
serum (Vector). Endogenous biotin activity of the 
cells was blocked with an avidin biotin blocking kit 
(Vector). The cells were incubated for 60 min with 
the  primary  antibody  (1:100  dilution,  Upstate)  in 
10% serum/PBS. For negative controls, cells were 
treated without antibody. The Mat-LyLu cells were 
then incubated for 60 min in biotinylated second-
ary antibodies (1:125 dilution, Dako) and processed 
for avidin-peroxidase staining as described by the 
manufacturer (Vectastain Kit, Vector) with diamino-
benzidine hydrochloride (DAB, Vector) as the chro-
mogen. Coverslips were mounted on slides using 
Entellan. 
Immunohistochemistry
VGSC  protein  expression  was  examined  both  in 
paraffin and frozen sections using standard immu-
nohistochemical  techniques.  Paraffin  sections  of 
4-5 µm thickness were deparaffinized with xylene 
and  rehydrated  through  graded  ethanol.  Endog-
enous peroxidase was suppressed by incubation in 
3% H2O2. Antigen retrieveal was performed in a mi-
crowave oven in EDTA (pH 8.0) for at least 30 min. 
The slides were incubated with 10% normal swine 
serum (Vector) in PBS, then with an “anti-sodium 
channel” primary antibody (1/100 dilution, Upstate) 
for 60 min. The slices were incubated with biotinyl-
ated secondary antibody (1:125 dilution, Dako) and 
processed using the avidin biotin-peroxidase sys-
tem (Vectastain Kit, Vector). Antibody binding was 
visualized using DAB (Vector). For the immunode-
tection of the VGSCs in frozen sections, the same 
protocol described above was carried out except for 
the deparaffinization and antigen retrieval steps. In 
all immunostaining a negative (omission of primary 
antibody) control was used. Image analyses were 
performed using an Olympus camera mounted on 
an  Olympus  light  microscope  in  conjunction  with 
Olympus DP71 software. 
RESULTS
Histopathological observations on Mat-
LyLu primary prostate tumors and the 
corresponding lung metastases
Subcutaneous implantation of 2x105 Mat-LyLu PCa 
cells  produced  primary  tumors.  Metastases  were 
observed in both the right and left side of the lungs 
in all animals. The smallest nodule was ~0.1 mm in 
diameter and the largest was ~1.5 mm. Represen-
tative photomicrographs of the paraffin section of 
one of the primary tumors and corresponding lung 
metastasis are shown in Figure 1. In histological ex-
aminations, the primary prostate tumors revealed a 
cellular and nuclear polymorphism. The tumor cells 
showed a polygonal cell structure and large, round 
to oval nuclei usually with a single nucleolus (Figure 
1A, 1B). Histological evaluation of the lungs showed 
numerous unencapsulated metastases (Figure 1C). 
Metastatic nodules were composed of small clus-
ters of round to irregularly shaped neoplastic cells 
and the cytological features of these lesions were 
generally similar to primary tumors (Figure 1D). 
VGSC mRNA expression in Mat-LyLu cells, 
Mat-LyLu primary prostate tumors and the 
corresponding lung metastases
Conventional RT-PCR was used for the screening 
of  Nav1.7  (the  predominant  subtype  of  VGSCs) 
expression  in  Mat-LyLu  cells,  Mat-LyLu  primary 
prostate tumors and corresponding lung metasta-
ses (Figure 2). PCR studies confirmed that the Mat-
LyLu cells expressed Nav1.7 mRNA. Nav1.7 mRNA 
expression was also detected in both the Mat-LyLu 
primary prostate tumor and corresponding lung me-
tastases specimens of the animals. Cytb5R internal 
control amplification showed highly consistent ex-
pression across all samples (Figure 2). No bands 
were  observed  in  negative  reverse  transcriptase 
and negative cDNA samples (data not shown).Yıldırım. Expression of voltage-gated sodium channel in primary tumors 425
J Clin Exp Invest   www.jceionline.org   Vol 4, No 4, December 2013
Figure 1.Photomicrographs of paraffin sections of a representative primary tumor and corresponding lung metastasis 
(hematoxylin and eosin staining). A: Primary tumor, low magnification, B: Primary tumor, high magnification, C: Lung 
metastasis, low magnification (arrows indicate metastatic lesion) and D: Lung metastasis, high magnification. Scale 
bars: 100 µm (A), 50 µm (B, D), 200 µm (C).
VGSC  protein  expression  in  Mat-LyLu  cells, 
Mat-LyLu  primary  prostate  tumors  and  the  corre-
sponding metastases.
Immunochemical staining demonstrated chan-
nel  protein  expression  in  Mat-LyLu  cells  (Figure 
3A). The VGSC protein localization was determined 
in  the  plasma  membrane  and  cytosolic  compart-
ments of cells. No expression of VGSC protein was 
detected in negative controls without the antibody 
(Figure 3B).
Primary  prostate  tumors  and  corresponding 
metastases were assessed for VGSC protein ex-
pression by immunohistochemistry in both the par-
affin  and  frozen  sections.  Immunohistochemical 
analyses  showed  that  VGSC  protein  expression 
was present both in primary Mat-LyLu prostate tu-
mors and the corresponding metastases (Figure 4). 
Tumor cells showed a positive diffuse staining pat-
Figure 2. Voltage-gated sodium channel/Nav1.7 mRNA 
expression  in  Mat-LyLu  cells,  Mat-LyLu  primary  pros-
tate tumor and the corresponding lung metastases. The 
electrophoresis results of Nav1.7 and cytochrome b5 re-
ductase (Cyt5bR) RT-PCRs are shown. Lanes; M: DNA 
Ladder, 1: Mat-LyLu PCa cells, 2: Mat-LyLu primary pros-
tate tumor, 3: Lung metastasis. Cytb5R internal control 
amplification showed highly consistent expression across 
all samples. Yıldırım. Expression of voltage-gated sodium channel in primary tumors 426
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tern for VGSC. At high magnification there is a posi-
tive staining of the tumor cells in the regions of the 
cytoplasm surrounding the nucleus. This immunore-
activity most likely represents cytoplasmic stores of 
protein available for transport to the surface mem-
brane and functional form of protein on the plasma 
membrane. In all primary tumor and lung metastasis 
(both small and large nodule) specimens exhibited 
VGSC positive staining and the obtained staining 
pattern was identical. Control sections (not shown) 
processed  without  primary  antibody  produced  no 
staining.
Figure 3. Immunocytochemical detection of voltage-gated sodium channel protein expression in cultured Mat-LyLu 
cells. A: Positive immunoreactivity of VGSC protein in Mat-LyLu cells. Membrane (arrowheads) and cytoplasmic (ar-
rows) staining is indicated. B: Negative control (omission of the anti-Na+ channel antibody) cells counterstained with 
hematoxylin. Scale bars: 50 µm.
Figure 4. Representative immunostaining of VGSC protein expression in primary prostate tumors and paired lung 
metastases. A: Equal VGSC immunohistochemical pattern between primary tumor and paired metastasis. Sections 
were prepared from formalin-fixed paraffin-embedded tissue specimens. B: Equal VGSC immunohistochemical pattern 
between primary tumor and paired metastasis. Sections were prepared from fresh-frozen tissue specimens. No expres-
sion of VGSCs was detected in negative controls without the primary antibody (data not shown). Scale bars: 100 µm in 
high magnification and 50 µm in low magnification. Yıldırım. Expression of voltage-gated sodium channel in primary tumors 427
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DISCUSSION
Functional  VGSC  expression  has  been  shown 
to  potentiate  metastatic  potential  by  enhancing  a 
range of in vitro metastatic cell behaviors, including 
directional motility [9,20,21] and Matrigel invasion 
[2,5,9]. More recently, blocking VGSC activity in pri-
mary tumors was shown to suppress lung metas-
tases in the Dunning Mat-LyLu prostate adenocar-
cinoma model of the Copenhagen rat [28]. This is 
the first demonstration of metastasis suppression in 
vivo by a highly specific VGSC blocker. In the pres-
ent study, it was studied the expression status of 
VGSC in primary tumors and their corresponding 
metastases  using  this  model.  VGSC  expression, 
which is observed in strongly metastatic Mat-LyLu 
PCa cells in vitro is also conserved when these cells 
form primary tumors and metastasize to the lungs 
upon  their  subcutaneous  injection  in  rats.  These 
results are consistent with the predominant role of 
VGSC in the metastatic progression of PCa [4,5,7].
In the present study the presence of VGSC in 
Mat-LyLu cells was confirmed by RT-PCR and im-
munocytochemistry at the mRNA and protein level. 
For tumor models generated from in vitro cell lines, 
it is important to confirm the presence of the rel-
evant target in the growing tumors and not just in 
the cell lines from which they originated, because in 
vivo cultivation can alter target gene and protein ex-
pression through changes in the microenvironment 
[29].  The  PCR  measurements  and  immunohisto-
chemical analyses confirmed expression of VGSC 
mRNA and protein in primary Mat-LyLu prostate tu-
mors, consistent with the predominant role of VGSC 
in metastatic PCa. [5,7]. 
Some studies have shown that VGSC mRNA 
and/or protein expression occurred in biopsies of 
human PCa [6,7], breast cancer [9], ovarian cancer 
[15] and colon cancer [16]. It was also shown that 
VGSC expressions in primary breast and ovarian 
cancer specimens strongly correlate with the pres-
ence  of  lymph  node  metastasis  [9,15].  However, 
it was not studied VGSC expression in metastatic 
lesions. This study demonstrated the existence of 
VGSC expression in metastatic site. 
Metastasis continues to be the most significant 
problem in the treatment of PCa cancer. As with 
all cancer, metastatic activity is the main cause of 
death  for  PCa  patients. An  understanding  of  the 
molecular basis of metastasis and the development 
of  anti-metastatic  therapies  enable  reductions  in 
patient morbidity and mortality [30]. Currently, the 
molecular basis of metastasis is relatively unknown. 
According to classical genetic selection hypothesis, 
a few rare cells within primary tumors acquire muta-
tions over time which provides some advantages. 
The advantageous genetic alterations enable these 
cells to escape the primary tumor and form metas-
tases at distant sites. However, more recent stud-
ies performed by DNA microarray analyses suggest 
that  the  acquisition  of  metastatic  phenotype  may 
happen relatively early during tumorigenesis (‘ab in-
itio’). This hypothesis is mainly based on the finding 
that several types of primary tumors harbor a gene-
expression  signature  associated  with  metastases 
[31]. In the present study, we found that PCa me-
tastases show VGSC expression as their primary 
tumor. In this respect, our results are consistent with 
the ab initio hypothesis. Actually, the two hypothe-
ses are not mutually exclusive and an ‘integrative 
view’ has been proposed which contemplates the 
presence of metastasis ‘initiation’, ‘progression’ and 
‘virulence’  genes  [32].  Metastasis  initiation  genes 
are supposed to provide an advantage in the pri-
mary tumor and perform functions which enable the 
tumor cells to escape the primary tumor. According 
to this view, VGSC which underlies tumor cell in-
vasion, motility, etc. [2,9,25] seems to possess the 
characteristics of a metastasis initiation gene. 
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